| pubmed-article:9637119 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9637119 | lifeskim:mentions | umls-concept:C0229671 | lld:lifeskim |
| pubmed-article:9637119 | lifeskim:mentions | umls-concept:C0677886 | lld:lifeskim |
| pubmed-article:9637119 | lifeskim:mentions | umls-concept:C0041242 | lld:lifeskim |
| pubmed-article:9637119 | lifeskim:mentions | umls-concept:C0543478 | lld:lifeskim |
| pubmed-article:9637119 | lifeskim:mentions | umls-concept:C0441771 | lld:lifeskim |
| pubmed-article:9637119 | lifeskim:mentions | umls-concept:C0441889 | lld:lifeskim |
| pubmed-article:9637119 | lifeskim:mentions | umls-concept:C0456389 | lld:lifeskim |
| pubmed-article:9637119 | lifeskim:mentions | umls-concept:C0445204 | lld:lifeskim |
| pubmed-article:9637119 | lifeskim:mentions | umls-concept:C0220901 | lld:lifeskim |
| pubmed-article:9637119 | lifeskim:mentions | umls-concept:C0021212 | lld:lifeskim |
| pubmed-article:9637119 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:9637119 | pubmed:dateCreated | 1998-7-9 | lld:pubmed |
| pubmed-article:9637119 | pubmed:abstractText | To evaluate the use of the pre-operative tumour-associated trypsin inhibitor (TATI) level and residual tumour size at primary surgery as a prognostic indicators for patients with Stage III epithelial ovarian cancer. | lld:pubmed |
| pubmed-article:9637119 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9637119 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9637119 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:9637119 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9637119 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9637119 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9637119 | pubmed:month | May | lld:pubmed |
| pubmed-article:9637119 | pubmed:issn | 0306-5456 | lld:pubmed |
| pubmed-article:9637119 | pubmed:author | pubmed-author:StenmanU HUH | lld:pubmed |
| pubmed-article:9637119 | pubmed:author | pubmed-author:LehtovirtaPP | lld:pubmed |
| pubmed-article:9637119 | pubmed:author | pubmed-author:PaavonenJJ | lld:pubmed |
| pubmed-article:9637119 | pubmed:author | pubmed-author:LeminenAA | lld:pubmed |
| pubmed-article:9637119 | pubmed:author | pubmed-author:ForssMM | lld:pubmed |
| pubmed-article:9637119 | pubmed:author | pubmed-author:VenesmaaPP | lld:pubmed |
| pubmed-article:9637119 | pubmed:author | pubmed-author:VartiainenJJ | lld:pubmed |
| pubmed-article:9637119 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9637119 | pubmed:volume | 105 | lld:pubmed |
| pubmed-article:9637119 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9637119 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9637119 | pubmed:pagination | 508-11 | lld:pubmed |
| pubmed-article:9637119 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:9637119 | pubmed:meshHeading | pubmed-meshheading:9637119-... | lld:pubmed |
| pubmed-article:9637119 | pubmed:meshHeading | pubmed-meshheading:9637119-... | lld:pubmed |
| pubmed-article:9637119 | pubmed:meshHeading | pubmed-meshheading:9637119-... | lld:pubmed |
| pubmed-article:9637119 | pubmed:meshHeading | pubmed-meshheading:9637119-... | lld:pubmed |
| pubmed-article:9637119 | pubmed:meshHeading | pubmed-meshheading:9637119-... | lld:pubmed |
| pubmed-article:9637119 | pubmed:meshHeading | pubmed-meshheading:9637119-... | lld:pubmed |
| pubmed-article:9637119 | pubmed:meshHeading | pubmed-meshheading:9637119-... | lld:pubmed |
| pubmed-article:9637119 | pubmed:meshHeading | pubmed-meshheading:9637119-... | lld:pubmed |
| pubmed-article:9637119 | pubmed:meshHeading | pubmed-meshheading:9637119-... | lld:pubmed |
| pubmed-article:9637119 | pubmed:meshHeading | pubmed-meshheading:9637119-... | lld:pubmed |
| pubmed-article:9637119 | pubmed:meshHeading | pubmed-meshheading:9637119-... | lld:pubmed |
| pubmed-article:9637119 | pubmed:meshHeading | pubmed-meshheading:9637119-... | lld:pubmed |
| pubmed-article:9637119 | pubmed:meshHeading | pubmed-meshheading:9637119-... | lld:pubmed |
| pubmed-article:9637119 | pubmed:meshHeading | pubmed-meshheading:9637119-... | lld:pubmed |
| pubmed-article:9637119 | pubmed:meshHeading | pubmed-meshheading:9637119-... | lld:pubmed |
| pubmed-article:9637119 | pubmed:meshHeading | pubmed-meshheading:9637119-... | lld:pubmed |
| pubmed-article:9637119 | pubmed:meshHeading | pubmed-meshheading:9637119-... | lld:pubmed |
| pubmed-article:9637119 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9637119 | pubmed:articleTitle | Pre-operative serum level of tumour-associated trypsin inhibitor and residual tumour size as prognostic indicators in Stage III epithelial ovarian cancer. | lld:pubmed |
| pubmed-article:9637119 | pubmed:affiliation | Department of Obstetrics and Gynaecology, University Central Hospital, Helsinki, Finland. | lld:pubmed |
| pubmed-article:9637119 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9637119 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9637119 | lld:pubmed |
